Misfolded protein intermediate (None in widespread use)

Misfolded protein intermediates are transient conformational forms that arise during the protein folding process when the polypeptide chain does not achieve its native, functional structure[7][4]. Some of these intermediates are benign and required for correct folding, but off-pathway intermediates can aberrantly self-associate, forming toxic oligomers or aggregates[7]. If not efficiently refolded or degraded, these misfolded intermediates may become seeding nuclei for amyloid fibril formation, contributing to a broad range of proteinopathies including Alzheimer's, Parkinson's, and other neurodegenerative diseases[2][3][8]. Most therapeutic strategies focus on upstream quality control (such as chaperones), degradation machinery, or downstream toxic aggregates, but misfolded intermediates themselves are not widely considered specific drug targets due to their transient and heterogeneous nature.

Other names

Protein folding intermediateFolding intermediateOff-pathway intermediate

Not directly targeted by drugs; however, some therapeutic approaches attempt to stabilize correct folding, promote clearance of intermediates, or inhibit aggregation downstream of intermediate formation.